By accessing or using nrimed.com you agree to be bound by the terms and conditions of the agreement which is included on this webpage. If you do not wish to be bound by this agreement, you may not access or use nrimed.com. The INR PLLC may modify this agreement at any time, without notifying you other than by the appearance of a changed agreement on the website. You agree to review this agreement each time you access this website to ensure that you are aware of its current contents. Your continued access or use of nrimed.com shall be deemed to be conclusive acceptance by you of the agreement in its modified form. Copyright ©2015, INR PLLC. The off-label methods of use and administration of certain cytokine antagonists, including etanercept, for the selected clinical disorders which are discussed on this website are patented inventions of the INR®; all rights to these patented methods of treatment are retained exclusively by TACT IP LLC. The INR® and the INR PLLC conduct a private medical practice. U.S. patents 6419944, 6471961, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323, and 8900583 all assigned to TACT IP, LLC; and Australian patent 758523.
You agree that the following disclaimer, which is more complete than the brief disclamer on the individual webpages of this website, shall be the full legal disclaimer that shall govern the use of any information obtained by you from nrimed.com. The medical information on this website is for educational purposes, to provide general information regarding certain new research developments in medicine. In the interest of public eduation several of these developments have been reported here as soon as possible after their publication. The information on this website should not be considered complete, nor should it be relied upon to establish or suggest a course of treatment for any particular individual. Although efforts will be made from time to time to update this information, it cannot be considered to be up-to-date, but rather to be only a partial report of the medical and research information available at the time this was written. The opinions presented on this website are subject to change, and should not be considered to be a treatment recommendation for any individual patient. Please note: INR physicians utilize etanercept for a limited number of off-label indications, including chronic post-stroke neurological dysfunction. INR physicians do not use etanercept for treating Parkinson’s disease, brain tumor, or carpal tunnel syndrome. Treatment recommendations can only be made in the course of an established physician-patient relationship following an in-person physical examination, medical history, and review of medical records. The information in this website should therefore not be used in place of a visit to your physician. Consult with your personal physician before beginning a new treatment regimen. You, the reader, take sole responsibility for interpretation and application of the information in this website. Mechanisms of disease remain incompletely understood and subject to constant revision as medical knowledge is developed. Medical opinions differ, and no representation is made that the information on this website represents current medical opinion or the standard of medical care. See California B&P 2234.1(4c): “Since the National Institute of Medicine has reported that it can take up to 17 years for a new best practice to reach the average physician and surgeon, it is prudent to give attention to new developments not only in general medical care but in the actual treatment of specific diseases, particularly those that are not yet broadly recognized in California”.
All medications have potential adverse effects. These side effects must be weighed against the possibility of beneficial therapeutic effects with regard to treatment of the underlying illnesses in question. Biologic TNF inhibitors have been associated with serious adverse reactions. Readers are referred to the prescribing information available from the pharmaceutical manufacturers for more complete information. This is generally available in the patient handouts accompanying the medications; from pharmacies; in the PDR; and on the manufacturer websites. The treatments used at the our medical clinics are generally for clinical disorders for which currently available treatments are either ineffective, only partially effective, or associated with other adverse effects. Neither our physicians, nor any of our employees or agents can guarantee that treatment at our clinics will result in clinical improvement and will not result in adverse effects. The information included in this website is for general informational and educational use only, and is subject to change pending the results of additional studies or additional clinical results reported in the medical literature. The information contained in this website is not meant to substitute for the opinion of the patient’s personal physician, and should not be construed as a treatment recommendation. Treatment recommendations can only be given after an in-office evaluation by an INR physician. Any recommendations regarding treatment must be viewed in the context of the treatment literature and discussions which take place during the in-office evaluation by one of our physicians, with particular consideration to the fact that many medications used at our clinics, while FDA approved for other uses, have not received FDA approval for the off-label indication selected by our physician. Please note: INR physicians utilize etanercept for a limited number of off-label indications. INR physicians do not use etanercept for treating Parkinson’s disease, brain tumor, or carpal tunnel syndrome. Off-label status of a drug or biologic means, by definition, that this medication has not been endorsed by the FDA to be either safe or effective for this off-label use, even if the medication has been FDA-approved for other medical uses. Perispinal etanercept for treatment of dementia is off-label around the world. Although randomized evidence supporting efficacy of epidural etanercept for sciatica has been published, there is not randomized evidence of efficacy of perispinal etanercept treatment for neurological disorders. We cannot guarantee, nor do we mean to imply, by any of the information in this website, that any single medication will necessarily lead to clinical improvement if administered for any given new patient. Screening or physician evaluation at the Institute of Neurological Recovery does not guarantee that treatment will be recommended or undertaken by the Institute physician. Treatment decisions will be made individually. Contraindications to medical treatment at the Institute may be determined at any stage in the evaluation process, even prior to physician physical examination.
Information in this website should not be interpreted as a recommendation to buy or sell any securities.
You agree to indemnify, defend, and hold harmless the Institute of Neurological Recovery and the INR PLLC and their employees, directors, officers and agents from and against all damages and costs, including all losses, expenses and reasonable attorney’s fees, resulting from any violation of this agreement by you or any of your agents or any activity related to your use of this website (including infringement of third parties United States or worldwide intellectual property rights or negligent or wrongful conduct) by you or your agent.You agree that the Institute of Neurological Recovery, INR and the INR PLLC and their employees, directors, officers and agents shall not have any liability to you under any theory of liability or indemnity in connection with your use of nrimed.com. Notwithstanding the foregoing paragraph, the total liability of Institute of Neurological Recovery(INR), shall not exceed the fees paid by the user for the particular information or service provided. Institute of Neurological Recovery® and INR® are federally registered trademarks of the INR or the INR PLLC.
Copyright ©2015, All Rights Reserved, INR PLLC. Reproduction in whole or in part is prohibited.